IDEXX Laboratories (IDXX) to Release Quarterly Earnings on Tuesday

IDEXX Laboratories (NASDAQ:IDXX) will likely be releasing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect IDEXX Laboratories to post earnings of $3.42 per share and revenue of $1.1187 billion for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.IDEXX Laboratories’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.53 earnings per share. On average, analysts expect IDEXX Laboratories to post $15 EPS for the current fiscal year and $16 EPS for the next fiscal year.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $564.26 on Monday. The business has a 50-day simple moving average of $589.55 and a two-hundred day simple moving average of $651.34. The company has a quick ratio of 0.90, a current ratio of 1.23 and a debt-to-equity ratio of 0.23. IDEXX Laboratories has a 52 week low of $465.00 and a 52 week high of $769.98. The stock has a market cap of $44.82 billion, a price-to-earnings ratio of 43.42, a PEG ratio of 3.45 and a beta of 1.58.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several analyst reports. Barclays reduced their target price on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. BTIG Research dropped their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Monday, April 27th. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Finally, Piper Sandler decreased their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating on the stock in a report on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

Insiders Place Their Bets

In other news, CEO Jonathan Jay Mazelsky sold 23,326 shares of the company’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at $54,975,125.30. This represents a 21.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares of the company’s stock, valued at $11,511,734.37. This represents a 8.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 45,957 shares of company stock worth $29,862,109. Insiders own 0.79% of the company’s stock.

Institutional Investors Weigh In On IDEXX Laboratories

Several large investors have recently added to or reduced their stakes in IDXX. Wellington Management Group LLP boosted its holdings in shares of IDEXX Laboratories by 318.1% in the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company’s stock worth $527,162,000 after purchasing an additional 592,834 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in IDEXX Laboratories by 37.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 952,223 shares of the company’s stock worth $644,208,000 after buying an additional 258,015 shares during the period. Zurich Insurance Group Ltd FI purchased a new position in IDEXX Laboratories during the third quarter worth $143,730,000. Invesco Ltd. increased its position in IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after acquiring an additional 181,955 shares during the last quarter. Finally, State Street Corp raised its stake in shares of IDEXX Laboratories by 4.0% in the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock valued at $2,473,817,000 after acquiring an additional 138,956 shares during the period. 87.84% of the stock is owned by institutional investors.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.